semaglutide heart attack Weight-loss drug to be offered to patients at risk of stroke or Semaglutide Cuts Heart Risk Beyond

Enhanced Liver Health Non-alcoholic fatty liver disease (NAFLD) is a common condition among people with obesity and type 2 diabetes

Studies show that patients on GLP-1 therapies experience modest increases in uric acid levels during the first months of treatment

This therapy is used to treat primarily musculoskeletal injuries such as cruciate ligament injuries, prolapsed intervertebral discs, back pain and osteoarthritis

USA 110 , 1247412479 (2013)

Studies are required to ascertain if homocysteine is a useful biomarker to steer a personalised supplement intervention or dietary intervention for positive health outcomes for mother and child

Weight loss medications in this class are not associated with transfusion-related complications